Full-Time
Manifold Bio
11-50 employees
Designs precision biologics using in vivo methods
No salary listed
Senior
Boston, MA, USA
Upload your resume to see how it matches 4 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- PhD or equivalent experience in neuroscience and/or molecular biology, biological engineering or a related field
- 10+ years of hands-on wet-lab experience, including 3+ years of startup/ biotech/pharma experience
- Experience going end-to-end from experimental design through execution and data interpretation
- Experience developing cell-based assays
- Design, execute, interpret, and iterate on cellular and biophysical assays to evaluate lead molecule activity and mechanism of action
- Help nominate a data-driven lead molecule selection funnel
- Conduct hypothesis-driven investigation of mechanism of action of lead molecules
- Serve as in vitro pharmacology/toxicology lead expert for DC nomination and IND-enabling studies
- Drive external work with CROs as needed
- Provide expertise on late-breaking advances in neuroscience and neurodegenerative diseases
Manifold Bio specializes in creating precision biologics for the pharmaceutical industry, focusing on drug design and development. Their main product is an in vivo drug design platform, which allows for testing drugs within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment, making it particularly effective for complex biologics. Unlike competitors, Manifold Bio's approach is the first of its kind, emphasizing in vivo testing to enhance drug development. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to advance the development of new therapeutics.
Company Size
11-50
Company Stage
Series A
Total Funding
$60.4M
Headquarters
Boston, Massachusetts
Founded
2020
Simplify's Take
What believers are saying
- Raised $40M in Series A funding, indicating strong market interest.
- Their platform could revolutionize in vivo testing by testing multiple molecules simultaneously.
- Strategic partnerships with multiple investors enhance growth and development opportunities.
What critics are saying
- Increased competition from companies like Insamo and Infinimmune.
- Rapid AI and ML advancements may outpace Manifold Bio's current technology.
- Regulatory challenges in in vivo testing could delay product development timelines.
What makes Manifold Bio unique
- Manifold Bio uses proprietary mCodes™ technology for protein multiplexing in drug design.
- Their in vivo drug design platform is the first of its kind globally.
- The company specializes in precision biologics, focusing on complex biologics development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 0%Manifold Bio secues $15M in Series A funding.
PALO ALTO, Calif.--(BUSINESS WIRE)--Playground Global, an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner. Ben focuses on identifying founders and companies that are revolutionizing engineered biology, building the future of emerging modality therapeutics development, and unlocking AI and ML workflows to refactor drug development. Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University. He became a Venture Associate a year later, and by 2022, he had led investments in two breakthrough biotech companies and was promoted to Venture Principal. In the last year, Ben has supported investments in Insamo (Board Observer and Lead Investor), Infinimmune (Board Director and Lead Seed Investor), Atomic AI (Board Observer and Lead Series A investor) and Amber Bio (Board Observer and Co-Led Seed Investment Round). He has also worked with Outpace Bio and Manifold Bio, where he is a Board Observer
Manifold Bio, a Boston, MA-based protein therapeutics company, raised $40M in Series A funding. The round was led by Triatomic Capital with participation from Section 32, FPV Ventures, Horizons Ventures, Tencent, Playground Global, Fifty Years, and FAST. With this funding, Triatomic Capital founding partner Jeff Huber will join Manifold Bio’s board of directors. Huber was previously founder and CEO of Grail and co-founder of Google’s life sciences efforts
Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and Tencent.
In the creation of a new drug, there comes a point where you have to finally put the molecule in a real creature — one at a time — and see if it actually does what you think it does. Manifold Bio’s molecular machinery could let a hundred molecules be tested simultaneously in a single living system, potentially upending the whole process. The drug discovery space has advanced a lot in the last few years, first with fast and cheap gene transcription, then with CRISPR, then with AI-powered proteomics. You don’t have to know what all of those do, however, to understand that in the end, no matter how much they accelerate fundamental research, in vivo testing remains a major bottleneck